SLC5A2 and heart failure: Several recent studies have confirmed that the benefits afforded by SGLT2 in terms of symptomatic relief and prognostic improvement in patients with heart failure far exceed those achieved by improving metabolism through glucose lowering, suggesting that improving symptoms and prognosis in heart failure is a class effect of SGLT2 inhibitors.